RTM added as distributor NeuraCeq®

Exciting news! Life Molecular Imaging’s NeuraCeq® 300 MBq/ml solution for injection (florbetaben 18F) will soon be available from Radboud Translational Medicine (RTM) in Nijmegen, The Netherlands. We're delighted to announce that the European Medicine Agency has approved the Type IB variation to the NeuraCeq EU dossier, adding RTM to the distribution network.

For more information on NeuraCeq®, including safety information, please visit: https://neuraceq.com/

RTM added as distributor NeuraCeq®

Other news

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...

Read more

First Patient Dosed with TLX250-CDx in Italy for ccRCC

First Patient Dosed with TLX250-CDx in Italy for ccRCC

The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...

Read more

18F-FDOPA now available

18F-FDOPA now available

Fluorodopa (18F) is now available for clinical studies and - with doctor's certificate - for routine...

Read more

RTM receives marketing authorisation for Fludeoxyglucose (18F)

RTM receives marketing authorisation for Fludeoxyglucose (18F)

We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018....

Read more

Interested in a collaboration?

Contact us to discuss the possibilities.